These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 20683392)

  • 1. Fast liquid chromatography-tandem mass spectrometry method for routine assessment of irinotecan metabolic phenotype.
    Corona G; Elia C; Casetta B; Toffoli G
    Ther Drug Monit; 2010 Oct; 32(5):638-46. PubMed ID: 20683392
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Determination of irinotecan, SN-38 and SN-38 glucuronide using HPLC/MS/MS: Application in a clinical pharmacokinetic and personalized medicine in colorectal cancer patients.
    Atasilp C; Chansriwong P; Sirachainan E; Reungwetwattana T; Puangpetch A; Prommas S; Sirilerttrakul S; Rerkarmnuaychoke B; Wongwaisayawan S; Sukasem C
    J Clin Lab Anal; 2018 Jan; 32(1):. PubMed ID: 28393405
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Determination of irinotecan and its metabolite SN-38 in rabbit plasma and tumors using a validated method of tandem mass spectrometry coupled with liquid chromatography.
    Park DJ; Won JH; Cho AR; Yun HJ; Heo JH; Hwhang TH; Lee DH; Kim WM
    J Chromatogr B Analyt Technol Biomed Life Sci; 2014 Jul; 962():147-152. PubMed ID: 24927278
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development and validation of a high-performance liquid chromatography-tandem mass spectrometry method for the simultaneous determination of irinotecan and its main metabolites in human plasma and its application in a clinical pharmacokinetic study.
    Marangon E; Posocco B; Mazzega E; Toffoli G
    PLoS One; 2015; 10(2):e0118194. PubMed ID: 25689738
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Liquid chromatographic-tandem mass spectrometric assay for the simultaneous quantification of Camptosar and its metabolite SN-38 in mouse plasma and tissues.
    Bardin S; Guo W; Johnson JL; Khan S; Ahmad A; Duggan JX; Ayoub J; Ahmad I
    J Chromatogr A; 2005 May; 1073(1-2):249-55. PubMed ID: 15909526
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quantitation of Irinotecan and its two major metabolites using a liquid chromatography-electrospray ionization tandem mass spectrometric.
    Zhang W; Dutschman GE; Li X; Ye M; Cheng YC
    J Chromatogr B Analyt Technol Biomed Life Sci; 2009 Oct; 877(27):3038-44. PubMed ID: 19648066
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A new UPLC-MS/MS method for the determination of irinotecan and 7-ethyl-10-hydroxycamptothecin (SN-38) in mice: application to plasma and brain pharmacokinetics.
    Goldwirt L; Lemaitre F; Zahr N; Farinotti R; Fernandez C
    J Pharm Biomed Anal; 2012 Jul; 66():325-33. PubMed ID: 22551773
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development and validation of an UPLC-MS/MS method for the determination of irinotecan (CPT-11), SN-38 and SN-38 glucuronide in human plasma and peritoneal tumor tissue from patients with peritoneal carcinomatosis.
    Gasthuys E; van Ovost J; Vande Casteele S; Cosyns S; Ceelen W; Van Bocxlaer J; Vermeulen A
    J Chromatogr B Analyt Technol Biomed Life Sci; 2024 Feb; 1233():123980. PubMed ID: 38215697
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High-performance liquid chromatographic assay with fluorescence detection for the simultaneous measurement of carboxylate and lactone forms of irinotecan and three metabolites in human plasma.
    Owens TS; Dodds H; Fricke K; Hanna SK; Crews KR
    J Chromatogr B Analyt Technol Biomed Life Sci; 2003 May; 788(1):65-74. PubMed ID: 12668072
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A sensitive and rapid liquid chromatography tandem mass spectrometry method for quantitative determination of 7-ethyl-10-hydroxycamptothecin (SN-38) in human plasma containing liposome-based SN-38 (LE-SN38).
    Khan S; Ahmad A; Ahmad I
    Biomed Chromatogr; 2003 Dec; 17(8):493-9. PubMed ID: 14648604
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics, metabolism, and excretion of irinotecan (CPT-11) following I.V. infusion of [(14)C]CPT-11 in cancer patients.
    Slatter JG; Schaaf LJ; Sams JP; Feenstra KL; Johnson MG; Bombardt PA; Cathcart KS; Verburg MT; Pearson LK; Compton LD; Miller LL; Baker DS; Pesheck CV; Lord RS
    Drug Metab Dispos; 2000 Apr; 28(4):423-33. PubMed ID: 10725311
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Simple and rapid determination of irinotecan and its metabolite SN-38 in plasma by high-performance liquid-chromatography: application to clinical pharmacokinetic studies.
    Escoriaza J; Aldaz A; Castellanos C; Calvo E; Giráldez J
    J Chromatogr B Biomed Sci Appl; 2000 Apr; 740(2):159-68. PubMed ID: 10821401
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development and validation of an UPLC-MS/MS method for the quantification of irinotecan, SN-38 and SN-38 glucuronide in plasma, urine, feces, liver and kidney: Application to a pharmacokinetic study of irinotecan in rats.
    Basu S; Zeng M; Yin T; Gao S; Hu M
    J Chromatogr B Analyt Technol Biomed Life Sci; 2016 Mar; 1015-1016():34-41. PubMed ID: 26894853
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An analytical method for irinotecan (CPT-11) and its metabolites using a high-performance liquid chromatography: parallel detection with fluorescence and mass spectrometry.
    Sai K; Kaniwa N; Ozawa S; Sawada J
    Biomed Chromatogr; 2002 May; 16(3):209-18. PubMed ID: 11920947
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of an LC-MS/MS Method for Measurement of Irinotecan and Its Major Metabolites in Plasma: Technical Considerations.
    Aoullay Z; Van Wijk XMR; Yanhui M; Meddah B; Lynch KL; Cherrah Y; Wu AHB
    Lab Med; 2022 Jan; 53(1):47-52. PubMed ID: 34351422
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High-performance liquid chromatography-mass spectroscopy/mass spectroscopy method for simultaneous quantification of total or free fraction of mycophenolic acid and its glucuronide metabolites.
    Figurski MJ; Korecka M; Fields L; Waligórska T; Shaw LM
    Ther Drug Monit; 2009 Dec; 31(6):717-26. PubMed ID: 19809389
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quantitative determination of liposomal irinotecan and SN-38 concentrations in plasma samples from children with solid tumors: Use of a cryoprotectant solution to enhance liposome stability.
    Nair S; Selvo NS; Stolarski A; Klee B; Federico SM; Stewart CF
    J Chromatogr B Analyt Technol Biomed Life Sci; 2024 Sep; 1245():124273. PubMed ID: 39146822
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Simultaneous determination of the lactone and carboxylate forms of irinotecan (CPT-11) and its active metabolite SN-38 by high-performance liquid chromatography: application to plasma pharmacokinetic studies in the rat.
    Yang X; Hu Z; Chan SY; Goh BC; Duan W; Chan E; Zhou S
    J Chromatogr B Analyt Technol Biomed Life Sci; 2005 Jul; 821(2):221-8. PubMed ID: 15936253
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A validated UPLC-MS/MS method to determine free and total irinotecan and its two metabolites in human plasma after intravenous administration of irinotecan hydrochloride liposome injection.
    Zhuang Q; Liu X; Sun Z; Wang H; Jiang J
    J Pharm Biomed Anal; 2019 Jun; 170():112-123. PubMed ID: 30921645
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Irinotecan (CPT-11) metabolism and disposition in cancer patients.
    Sparreboom A; de Jonge MJ; de Bruijn P; Brouwer E; Nooter K; Loos WJ; van Alphen RJ; Mathijssen RH; Stoter G; Verweij J
    Clin Cancer Res; 1998 Nov; 4(11):2747-54. PubMed ID: 9829738
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.